DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer
(Thomson Reuters ONE) -
Press Release
Bagneux, France, June 26, 2015
DBV Technologies Proudly Welcomes
Dr. Hugh Sampson as Chief Scientific Officer
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced the
appointment of Dr. Hugh Sampson as Chief Scientific Officer (CSO). In this new
role and in partnership with Dr. Dupont, chairman of the Company's Scientific
Advisory Board, Dr. Sampson will lead DBV's research team, pursuing new Viaskin®
applications for the treatment of food allergies, while also supporting the
Company's clinical development teams. Dr. Sampson's appointment as CSO will
become effective on November 1, 2015. Dr. Sampson will also continue serving as
an advisor to the Company, as well as Director of the Research Center at the
Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York,
NY.
Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV
Technologies, said: "Today marks a very important day for us. One of the world
leaders in medical research in food allergy and immunology is joining our
leadership team, and we are honored to welcome him to DBV. We believe that
Hugh's vision and unique experience will bring a lot of value as we seek to
expand our platform in the coming years. By joining forces, we hope to make
great strides both in research and clinical development. We share the same
commitment to innovation and the same ambition to change the lives of millions
of food allergic patients."
Dr. Hugh Sampson, Chief Scientific Officer, said: "I am very excited to join the
DBV team and look forward to exploring the potential of this innovative
platform. In my short tenure as a member of the DBV Scientific Advisory Board, I
have been very impressed with the dedication and energy of everyone at DBV and
their desire to understand the basic science underlying this immunotherapeutic
approach, which has the potential to benefit millions of food allergic
patients."
Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of
Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food
Allergy Institute; and Dean of Translational Biomedical Science at The Mount
Sinai Medical Center. He received his M.D. from the State University of New York
at Buffalo School of Medicine. Dr. Sampson's research interests have focused on
food allergic disorders, including work on the immunopathogenic role of food
hypersensitivity in atopic dermatitis, the pathogenesis of food-induced
anaphylaxis, the characterization of food-induced gastrointestinal
hypersensitivities, the characterization of food allergens, and novel
immunotherapeutic strategies (recombinant engineered protein, plasmid DNA,
peptide, etc.) for treating food allergies. His research has been funded by a
number of grants from the National Institutes of Health (NIH) and private
foundations. He is the Principal Investigator of the NIH-sponsored Consortium of
Food Allergy Research (CoFAR). He is also former President of the American
Academy of Allergy Asthma and Immunology (AAAAI).
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing in
prevalence. DBV Technologies, incorporated in France in 2002, has developed a
proprietary, patented technology for administering an allergen to intact skin
while avoiding transfer to the blood, and thus lowering the risk of a systemic,
allergic reaction in the event of accidental exposure. DBV Technologies is
focusing on food allergies, including milk and peanut, for which there are
currently no effective treatments. DBV Technologies has designed two products
candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program
for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy
designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American
Depositary Shares (each representing one-half of one ordinary share) (Ticker:
DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements forward-looking
statements that are not promises or guarantees and involve substantial risks and
uncertainties. The Company's product candidates have not been approved for sale
in any jurisdiction. Among the factors that could cause actual results to
differ materially from those described or projected herein are uncertainties
associated generally with research and development, clinical trials and related
regulatory reviews and approvals, the risk that historical preclinical results
may not be predictive of future clinical trial results, and the risk that
historical clinical trial results may not be predictive of future trial
results. A further list and description of these risks, uncertainties and other
risks can be found in the Company's regulatory filings with the French Autorité
des Marchés Financiers, the Company's Securities and Exchange Commission filings
and reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2014 and future filings and reports by the Company. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information, future
events or circumstances or otherwise.
DBV Technologies Contacts
Nathalie Donne Susanna Mesa
Director, Corporate Communication & VP Finance, US Investor Relations &
Business Development Strategy
Tél. : +33(0)1 55 42 78 72 Tél. : +1 917-346-3447
nathalie.donne(at)dbv-technologies.com susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tél. : +1-212-223-4017 Tél. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com caroline(at)alizerp.com
HSamspon_EN:
http://hugin.info/156437/R/1931701/694741.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1931701]
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 403212
Anzahl Zeichen: 8041
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 218 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Proudly Welcomes Dr. Hugh Sampson as Chief Scientific Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
